Abdul Mannan: The Dual Biology of the Sickle Cell Mutation
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn about an article by Gavin Band et al. published in Nature, adding:
“The sickle mutation is not simply ‘protective’.
It depends on whether you inherit one copy or two.
That is the whole paradox.
Here’s the simple version:
- HbAS protects because the parasite creates local hypoxia inside the red cell
- That triggers limited HbS polymerisation
- The infected red cell sickles
- A working spleen clears it, parasite included
- Less PfEMP1 reaches the cell surface, so there is less adhesion and rosetting
But HbSS is different:
- The spleen is often lost early through repeated infarction
- Red cells are already under sickling stress
- There is no HbA buffer
- Baseline anaemia leaves little reserve
- Malaria then adds haemolysis on top of haemolysis
So the same mutation can act like a trap in HbAS, but becomes a liability in HbSS.
A 2022 Nature paper by Band et al. added another layer: HbS protection also depends on parasite genotype, with Pfsa1, Pfsa2 and Pfsa3 loci linked to parasites that can cause severe malaria despite HbS.
For trainees, this is a beautiful teaching point:
Genetics is never isolated from environment.
And malaria wrote part of the sickle cell story.
What is your favourite example of evolution shaping haematology?”
Title: Malaria protection due to sickle haemoglobin depends on parasite genotype
Authors: Gavin Band, Ellen M. Leffler, Muminatou Jallow, Fatoumatta Sisay-Joof, Carolyne M. Ndila, Alexander W. Macharia, Christina Hubbart, Anna E. Jeffreys, Kate Rowlands, Thuy Nguyen, Sónia Gonçalves, Cristina V. Ariani, Jim Stalker, Richard D. Pearson, Roberto Amato, Eleanor Drury, Giorgio Sirugo, Umberto d’Alessandro, Kalifa A. Bojang, Kevin Marsh, Norbert Peshu, Joseph W. Saelens, Mahamadou Diakité, Steve M. Taylor, David J. Conway, Thomas N. Williams, Kirk A. Rockett, Dominic P. Kwiatkowski

Other posts featuring Abdul Mannan on Hemostasis Today.
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?
-
Nov 17, 2026, 23:33Remi Remakanth: The Role of Transfusion Medicine in HLA Antibody Testing and Transplant Desensitization